2026-06-18 ノースカロライナ州立大学（NC State）
＜関連情報＞
- https://news.ncsu.edu/2026/06/researchers-find-rare-mutation-doesnt-always-result-in-blood-cancer/
- https://www.pnas.org/doi/10.1073/pnas.2507773123
一般集団におけるJAK2V617Fクローン増殖の数理モデル化 Mathematical modeling of JAK2V617F clonal expansion in a general population cohort
Jordan Snyder, Morten Andersen, Johanne Gudmand-Høyer, +8 , and Thomas Stiehl
Proceedings of the National Academy of Sciences Published:June 17, 2026
DOI:https://doi.org/10.1073/pnas.2507773123
Significance
This study leverages the Danish General Suburban Population Study to track the progression of the cancer-associated mutation JAK2V617F in individuals from the general population before the onset of disease. Unlike previous research on diagnosed patients, this work reveals that many individuals with the mutation show no clonal expansion, or even show clonal contraction, challenging existing assumptions about early myeloproliferative neoplasms development. These findings offer insights into the initial phases of the disease and may help improve patient outcomes through tailored monitoring and intervention strategies.
Abstract
The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a group of blood cancers characterized by overproduction of one or more types of blood cells, which can lead to thrombosis and other complications. MPNs develop slowly and are driven by a relatively small set of mutations in the hematopoietic stem cells (HSCs). Their slow development (over the course of decades) affords a unique opportunity to study their onset, but until recently few data have been available from individuals not yet showing overt disease. Thanks to the ambitious Danish General Suburban Population Study conducted in suburban Zealand, Denmark, we have identified a () cohort of individuals harboring the most common driver mutation in MPN (namely JAK2V617F) and have obtained follow-up measurements of their variant allele fraction (VAF) spanning over 10 y. We show that these data are consistent with a Moran model governing the competition between healthy and mutated HSCs, and estimate the selective advantage of the mutant clone for each individual. Notably, we find that for many individuals, the change in VAF over many years is statistically consistent with zero, or even negative, selective advantage. This is in contrast to prior studies that have focused on patients diagnosed with overt MPN disease, in whom the mutant cells are almost always found to outcompete the healthy cells. Our results have implications for our understanding of the very early phases of MPN disease, and may contribute to early detection and personalized prediction of disease progression.
